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Abstract: Here we report an overview of our synthetic, spectro-
scopic and structural studies of technetium and rhenium nitrosyl 
complexes. We review the results from various notes and short 
papers reported over the past 15 years and discuss their signifi-
cance in terms of radiopharmaceutical design. 
A single new complex is reported, the ReI-NO complex [ReICl2
(NO)(py-N(Et)-py)], in which the tridentate ligand di-(2-
picolyl)(N-ethyl)amine,  (py-N(Et)-py), is coordinated in a me-
ridional manner. This complex was synthesized from the reac-
tion of the ReI-nitrosyl complex ReCl2(NO)(NCMe)3] and the 
neutral tri-amine ligand py-N(Et)-py in methylene chloride un-
der argon. The bright red species was isolated chromatograph-
ically and recrystallized from CH2Cl2/MeOH under diethylether. 
The infrared spectrum displays ν(N=O) at 1668 cm-1. The ESI 
mass spectrum displays the parent peak, [ReCl(NO)(py-N(Et)-
py)]+, at 479 m/z; and a second peak from [ReCl2(NO)(py-N(Et)
-py)]+ at 414 m/z. 
The X-ray crystal structure established this species to contain 
mutually trans-chloride ligands, with the tridentate ligand coor-
dinated in a meridional manner. The nitrosyl ligand displays 
multiple bonding throughout, with a Re-N bond length of 1.742
(2) Å and nitrogen-oxygen bond length of 1.202(3) Å. The Re-
N-O bond angle is nearly linear, at 177.3(2)°. There is signifi-
cant deviation from ideal octahedral geometry, mainly due to 
the small bite angle of the tridentate ligand. The Re-N bond 
length to the amine nitrogen trans- to the nitrosyl nitrogen is 
significantly longer than the bonds to the two aromatic amine 
nitrogens, as expected. {2.231(2)Å vs 2.085(2)Å and 2.091(2)
Å}. A review of literature values for nitrosyl complexes with 
various ligands bound to the coordination site trans- to the ni-
trosyl group shows only minor variations in the M-N-O bond 
angle. 
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1. INTRODUCTION 
Rhenium nitrosyl chemistry has received increased scrutiny 
recently, pertaining to hydrogen related catalyses. Technetium, 
rhenium’s second row congener, is radioactive. Its long-lived 
isotope 99Tc, is a weak beta emitter with a half-life of 211,000 
years, which essentially prohibits analogous studies in catalysis. 
Technetium’s short-lived isotope 99mTc, (half-life of about 6 
hours) is used extensively in SPECT-based (Single-Photon 
Emission Computed Tomography) diagnostic imaging agents 
for nuclear medicine. Technetium-99m is used in 20 million 
diagnostic nuclear medical procedures every year. Technetium-
nitrosyl complexes for application in radiopharmaceutical de-
velopment have been largely overlooked. 
Both PET (positron emission tomography) and SPECT imaging 
probes contribute to modern clinical medicine, particularly in 
cardiology, oncology and neurology. It should be emphasized 
that the installed base of SPECT-capable cameras is still far 
larger than that for PET devices, and further, PET is severely 
limited in its utility and its availability. In the United States, in 
2008, SPECT devices outnumbered PET by over 12,000 to 
1,000 [1,2]. Furthermore, the continuing advancement in 
SPECT imaging technologies, particularly those designed for 
specific procedures, is proceeding rapidly [3-7]. Thus the role of 
SPECT imaging agents, particularly those incorporating Tc-
99m, remains very important in providing cost effective clinical 
information that is readily accessible at all times to a wide pop-
ulation. These facts continue to make exploration of the basic 
coordination chemistry of technetium of prime importance, in 
spite of the US federal funding agencies’ lack of insight and 
perspective in this matter. 
The search for new SPECT imaging probes lies at an intersec-
tion of inorganic, organic and medicinal chemistry. Critical to 
the development of new imaging agents is the availability and 
utility of core structural building blocks upon which the rest of 
the molecule is built.  For SPECT imaging agents, the techneti-
um-core is essential to designing new and novel complexes, and 
the availability of new metal-cores is thus important. A transi-
tion metal core is defined here as a recurrent molecular founda-
tion of inherent structural and redox stability containing the 
metal ion upon which the molecule is constructed. The remain-
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ing coordination sites of the metal ion are available for substitu-
tion in order to complete the molecular geometry and supple-
ment the stability of the metal core. Through choice and orienta-
tion of donor groups in the chelating ligand design, the complex 
is provided with additional stability as well as a means of inte-
grating or attaching specific targeting pendant pharmacophores. 
Taken as a whole, the metal core, in conjunction with an appro-
priate chelating ligand and pharmacophore, is what determines 
the overall charge, shape, lipophilicity and consequently the 
utility of the chelated metal complex as an imaging probe. 
The significance of novel inorganic chemistry that can further 
radiopharmaceutical design of new technetium complexes can 
be traced back to the initial identification of the TcVO core and 
its subsequent use in the design of clinically useful agents such 
as 99mTcOV-HMPAO, 99mTcOV-ECD, 99mTcOV-MAG3, and 
99mTcOV-TRODAT; agents that are currently used world-wide 
in the diagnostic nuclear medicine clinics.[8,9] Similarly, sever-
al new preclinical agents currently under evaluation can be at-
tributed to the impact of identifying the metal-tricarbonyl {MI
(CO)3} core as a viable stable metal core[10-15].  This {TcI
(CO)3} core has been under intense scrutiny for the past decade, 
with new preclinical agents currently under development [16-
18]. The list of component cores in technetium imaging 
agents currently employed in the clinic is short. The most wide-
ly utilized is the Tc(V)-oxo core, which is found in a number of 
imaging agents. The Tc(V)-oxo core is distinguished by its sta-
bility and its ability to accommodate a variety of different func-
tional groups in its four available coordination sites. This allows 
its chemical and biological properties to be readily manipulated 
with various chelating ligands designed to supplement the metal
-oxo core. Among the low oxidation state species, the Tc(I)-core 
is found in {TcI-(MIBI)6}, which is inert to ligand substitution. 
A more structurally versatile Tc(I) species is the Tc(I)-
tricarbonyl core, {TcI(CO)3}, which retains three carbonyl 
groups locked in a facial arrangement, allowing ligation at its 
remaining three coordination sites. This Tc(I) core has been 
under intense scrutiny for the past decade, with many deriva-
tives synthesized, characterized and evaluated in preclinical 
studies. Its versatility however is limited in that only three facial 
coordination sites are available for ligation to complete the met-
al octahedral geometry. This restriction greatly reduces the utili-
ty of the core in radiopharmaceutical design. 
Our recent efforts in developing new technetium chemistry led 
us to identify the M-nitrosyl {M-NO, where M = Re or Tc} as a 
novel core worth further investigation. While some chemistry 
with this core has been reported [19], it has yet to be exploited 
in the design of new technetium radiopharmaceuticals, mainly 
due to the lack of useful precursors and a thorough understand-
ing of the ligand preferences required for synthesis of stable 
metal complexes.  To date the Tc-NO core has been identified 
almost exclusively in formal [+2] or [+1] oxidation states [20]. 
The de facto synthetic precursor for technetium nitrosyl chemis-
try has been (Bu4N)[TcII(NO)Cl4], [1] a Tc(II) species that is 
five coordinate and contains easily replaceable chloride ligands, 
making it very reactive in ligand exchange reactions. However, 
a major drawback with respect to radiopharmaceutical chemis-
try is that this TcII-NO precursor is routinely reduced to prod-
ucts containing the TcI-NO core, even under ambient reaction 
conditions. Simple ligand exchange reactions under mild reac-
tion conditions are invariably complicated by concomitant re-
dox chemistry that lowers yields and creates by-products.  
The rhenium(II) nitrosyl complex (Bu4N)2[ReII(NO)Cl5], [21], 
closely related to (Bu4N)[TcII(NO)Cl4], has been reported, but it 
has yet to be thoroughly explored in reactions relevant to radio-
pharmaceutical utility. Periodic trends suggest technetium and 
rhenium chemistry will closely parallel each other, however this 
trend does not generally hold with redox reactions. The devel-
opment of parallel technetium- and rhenium-nitrosyl chemistry 
and identification of analogous complexes is necessary from a 
radiopharmaceutical chemistry perspective. Structural analogs 
of technetium complexes with cold rhenium are important in 
various chromatographic characterization studies, which are not 
practical from a waste management perspective using the long-
lived isotope 99Tc. Furthermore, in vitro biological assays such 
as competitive receptor binding studies, where 3H-ligands are 
used with non-radioactive Re-complexes because β- emissions 
from 99Tc-complexes complicate the analysis. We thus em-
barked on a cursory exploration of substitution reactions of 
technetium and rhenium nitrosyl complexes in oxidations states 
(I) and (II). Here we summarize our results, most of which have 
been previously presented in notes and short papers. We discuss 
the big picture, and how this chemistry might be utilized in radi-
opharmaceutical development. Additionally, a single new com-
pound, [ReCl2(NO)(py-N(Et)-py)], a Re(I) nitrosyl complex 
with a tridentate amine ligand is presented. 
 
 2. EXPERIMENTAL 
Reagents and solvents were used as received unless otherwise 
stated. The technetium nitrosyl precursor (Bu4N)[Tc(NO)Cl4] 
was prepared by method of Thornback et al.[22] ReCl2(NO)
(NCMe)3] was prepared by method of Jaing. [23] Routine infra-
red spectra were obtained on a Perkin–Elmer Spectrum One FT-
IR Spectrometer. Mass spectra were recorded on a Bruker Dal-
tonics APEXII 3 Tesla Fourier Transform Mass Spectrometer 
(Ion Cyclo-tron Resonance Mass Spectrometer). See Table 1 for 
summation of X-ray crystallographic data set collection and 
refinement parameters. 
3. RESULTS AND DISCUSSION 
[ReCl2(NO)(py-N(Et)-py)] - A 0.025g sample of di-(2-picolyl)
(N-ethyl)amine (py-N(Et)-py) (0.098 mmol) and 0.045g ReCl2
(NO)(NCMe)3] (0.012 mmol) were combined in 40 mL of 
methylene chloride under argon. Stir at RT for 48 h. Chromato-
graph the resulting golder-orange solution on silica, eluting with 
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5% methanol in methylene chloride. Two mobile bands of pur-
ple and cherry-red color were isolated. The red band produced 
red crystals when layered with diethylether. Yield 12 mg (22 
%). CCDC 1027523. 
IR(neat) (cm-1): 1668, ν(N=O), (vs). ESI(+) Mass Spectrum (m/
z): 414, [ReCl2(NO)(py-N(Et)-py)]+; [ReCl(NO)(py-N(Et)-py)]
+
, 479 m/z. 
For details of the synthetic procedures and structural analyses, 
please see the following refernces: 
Compounds Reference 
[ReBr2(NO)(NCMe){py-NH~N(-py)2}]   [24] 
[Re(NO){py-NH-N(-py)2}](BPh4)2  [25] 
[TcCl2(NO)(py-N(Et)-py)]     [24] 
[TcCl(NO)(py-N(Et)-py)(PPh3)]Cl  [24] 
[TcCl(NO)(py-NH-NH-py)]Cl    [24] 
[TcCl(NO)(py-NH-NH~py)(PPh3)]Cl   [24] 
[TcCl(NO)(Spy)(PPh3)2]     [26] 
[Tc(NO)(Spy)2(PPh3)]     [26] 
[TcCl2(NO)(HN=NC5H4N)(PPh3)]   [27] 
[TcCl2(NO)(py)3]      [28] 
[TcCl2(NO)(Ph2P-N(pr)-PPh2)], (fac)   [29] 
[TcCl2(NO)(Ph2P-N(pr)-PPh2)], (mer)   [29] 
exptl crystal colour                                                 red 
exptl crystal density diffrn                              2.143 
exptl crystal F 000                                                      492 
exptl crystal size -max, mid, min                 0.280, 0.190, 0.110 
exptl absorpt coefficient -mu                               7.964 
shelx estimated absorpt -T min, max                  0.214, 0.475 
exptl absorpt correction type                      multi-scan 
exptl absorpt correction -T min, max          0.115142, 0.214051 
exptl absorpt process details     SADABS (Sheldrick, 2009) 
diffrn radiation wavelength                            0.71073 
diffrn radiation type                                              MoK\α 
diffrn measurement method                                  φ and ω scans 
diffrn reflns number                              5341 
diffrn reflns limit -h min, max                                  -10, 10 
diffrn reflns limit -k min, max                                       -12, 12 
diffrn reflns limit -l min, max                                             0, 19 
diffrn reflns theta –min, max                       1.569, 31.708 
reflns number -total                                                   5341 
reflns number -gt                                                       5212 
reflns threshold expression                    I > 2\σ(I) 
refine ls number reflns              5341 
refine ls number parameters            201 
refine ls number restraints                0 
refine ls R factor -all                               0.0207 
refine ls R factor -gt                                0.0200 
refine ls wR factor -ref                            0.0527 
refine ls wR factor -gt                               0.0523 
refine ls goodness of fit -ref       1.046 
Chemical formula      C14H17Cl2N4ORe 
Chemical formula weight                      514.41 
Space group crystal system                        triclinic 
Space group                                          P-1 
Cell length a               7.4116(5) 
Cell length b                             8.6967(5)(5) 
Cell length c                              13.3915(10) 
Cell angle alpha                               86.631(3) 
Cell angle beta                            75.7804(19) 
Cell angle gamma                           72.3119(17) 
Cell volume                                    797.05(9) 
Cell formula units Z                                        2 
Cell measurement -temperature                       100(2) 
Cell measurement -reflns used                           9650 
cell measurement –theta min, max                            2.46, 31.63 
exptl crystal description                                 block 
Instrumentation - Bruker X8 Kappa DUO four-circle diffrac-
tometer, Bruker APEX2 CCD. The instrument was purchased 
with the help of funding from the National Science Foundation 
(NSF) under Grant Number CHE-0946721. Refine Special De-
tails - Refined as a 2-component non-merohedral twin.   Similar 
ADP and Hirshfeld restraints applied to all atoms.  
4. DISCUSSION 
The synthesis of the nitrosyl precursor (Bu4N)[TcII(NO)Cl4] 
involves the reductive nitrosylation of the Tc(V)-oxo complex 
(Bu4N)[TcVOCl4] with excess hydroxylamine-HCl in methanol 
[1]. This five coordinate, air stable Tc(II)-NO complex is very 
Table 1 
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reactive with most conventional ligand types at ambient reaction 
conditions, seemingly making it well suited for ligand evalua-
tion screening towards the development of imaging agents. 
However preliminary results proved problematic, with very 
poor yields and mixtures of products that were consistently un-
stable. All products identified from reactions with this precursor 
were reduced Tc(I)-NO species.  
Reactions of (Bu4N)[TcII(NO)Cl4] with stoichiometric quantities 
of the tridentate bis-phosphine-amine ligand Ph2PCH2CH2N(Et)
CH2CH2PPh2, {PNP} in various solvents and at various temper-
atures, yielded complex mixtures of products as determined by 
infrared spectroscopy and chromatography. Complicating this 
scheme was the fact that these products were unstable, reacting 
further upon sitting in solution. It became apparent that the Tc
(II) oxidation state of (Bu4N)[TcII(NO)Cl4] was a significant 
complicating factor in these reactions, especially with redox 
active ligands like the phosphines in the tridentate PNP ligands.  
The PNP ligands in these reactions are both, facilitating the an-
ticipated ligand exchange reaction and serving as a reducing 
agent, in converting the Tc(II)-precursor to the Tc(I) products. 
The mer- and fac- isomers of the Tc(I) complex [TcICl2(NO)
(PNP)] are the major products isolated from these reactions in 
acetonitrile and methanol respectively, although yields in both 
reactions were very low. The X-ray crystallographic studies of 
these two complexes confirm the presence of linear nitrosyl 
groups, which are displayed below as ORTEP diagrams in Fig-
ure 1. The Tc-N-O bond angles for the facial complex is 177.9
(4)° and for the meridional complex is 173.0(4)°. This 5° differ-
ence in bond angle likely reflects the difference in ligands trans- 
to the TcI-NO core, which are an aliphatic amine and a chloride, 
respectively. These results leads to the conclusion that the redox 
active TcII-NO precursor (Bu4N)[TcII(NO)Cl4] creates signifi-
cant synthetic complications, and that better yields of stable 
products would come from a TcI-NO precursor.		
The air stable TcI-NO complex [TcICl2(NO)(HOMe)(PPh3)2] 
was synthesized from (Bu4N)[TcII(NO)Cl4]. It contains easily 
replaceable methanol and chloride ligands, which makes this Tc
(I)-NO complex well suited for further evaluation in imaging 
probe design.  Syntheses using this Tc(I) precursor proved ef-
fective, giving higher yields and stable TcI-NO products, by 
effectively eliminating the complicating redox chemistry associ-
ated with the Tc(II) precursor (Bu4N)[TcII(NO)Cl4]. The reac-
tion sequence depicted in Figure 2 below shows the redox reac-
tions involved in converting pertechnetate to a TcI-NO precur-
sor.  
Reactions of the Tc(I) precursor [TcICl2(NO)(HOMe)(PPh3)2] 
with a series of bi-, tri-, tetra- and pentadentate ligands give 
promising results. Though far from exhaustive, these prelimi-
nary studies suggest that the structurally versatile family of pol-
yamine ligands form stable complexes and warrant further eval-
34
Figure 1.  ORTEP diagrams of the TcI-NO meridional [TcICl2(NO)(PNP)] and facial [TcICl2(NO)(PNP)] complexes. 
TcVIIO4- [TcVOCl4]- [TcIINOCl4]- [TcICl2(NO)(HOMe)(PPh3)2]-
HCl HONH2-HCl PPh3
 
 
Figure 2: Sequential reduction reactions necessary to generate the Tc(I)-NO precursor [TcICl2(NO)(HOMe)(PPh3)2] from pertechnetate. 
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uation in radiopharmaceutical design and development. 
Using the TcI-NO precursor [TcICl2(NO)(HOMe)(PPh3)2], with 
stoichiometric amounts of the bidentate ligand 2-
mercaptopyridine and a proton scavenger gives good yields of 
the structurally characterized Tc(I) complex [TcICl(NO)(Spy)
(PPh3)2]. Similar reaction of [TcICl2(NO)(HOMe)(PPh3)2] and 
an excess of 2-mercaptopyridine and proton scavenger gives 
high yields of the bis-mercaptopyridine adduct [TcI(NO)(Spy)2
(PPh3)]. The ORTEP diagrams of these two complexes are 
shown in Figure 3 below. In both structures there is significant 
Figure 3 – ORTEP diagrams of the TcI-NO mercaptopyridine complex [TcICl(NO)(Spy)(PPh3)2] and the TcI-NO bis-mercaptopyridine complex 
[TcI(NO)(Spy)2(PPh3)]. 
deviation from octahedral geometry that is a result of distortion 
introduced by the small bite angle of the bidentate ligand. Em-
ploying this TcI-NO precursor significantly reduces the difficul-
ties encountered earlier when employing the TcII-NO precursor 
(Bu4N)[TcII(NO)Cl4]. In both of these reactions of the TcI-NO 
precursor, no chromatographic purification was needed, yield-
ing X-ray quality crystals (Figure 3). 
To directly compare the reactions of the TcI-NO and TcII-NO 
precursors, each was reacted with the neutral, tridentate ligand 
bis-2-picolyl(N-ethyl)amine. Reaction with (Bu4N)[TcII(NO)
Figure 4 – ORTEP diagrams of the TcI-NO complex [TcICl2(NO)(py-N(Et)-py)] in which the N3 ligand is coordinated in a facial manner, and the 
cationic TcI-NO complex [TcICl(NO)(PPh3)(py-N(Et)-py)]+. 
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Cl4] again gave a complex mixture of products that required 
chromatographic separation. The predominant stable product 
isolated was the neutral Tc(I) complex [TcICl2(NO)(py-N(Et)-
py)], which incorporates the tridentate ligand in a facial orienta-
tion, and was isolated in 23% yield. This same tridentate ligand, 
when reacted with the reduced TcI-NO precursor  [TcICl2(NO)
(HOMe)(PPh3)2], gave a much higher, 47% yield of the cationic 
complex [TcICl(NO)(PPh3)(py-N(Et)-py)]Cl. Here too, the tri-
dentate ligand is coordinated in a facial orientation, however, 
given the presence of PPh3 in the precursor, the isolated product 
retains a phosphine coligand coordinated trans- to the aliphatic 
amine. The charge difference found in these two complexes is 
due to the retention of a PPh3 in the latter product and its ab-
Figure 5 – ORTEP diagram of the ReI-NO complex [ReICl2(NO)(py-N
(Et)-py)] in which the N3 ligand is coordinated in a meridional manner. 
sence in the former. ORTEP diagrams of these two complexes 
are illustrated in Figure 4. (Note that the chloride ion from the 
cationic species has been omitted for clarity.)  
Similar in nature to the neutral, TcI-NO precursor [TcICl2(NO)
(HOMe)(PPh3)2] is the neutral, ReI-NO precursor [ReICl2(NO)
(NCMe)3]. While the technetium species has two tri-
phenylphosphine ligands that, by virtue of their steric bulk and 
the nature of the phosphine-technetium bond, can be difficult to 
replace, the rhenium complex has three acetonitrile ligands 
which are quite easy to replace. We employed these two struc-
turally similar complexes in our attempt to synthesize directly 
analogous Tc(I) and Re(I) complexes of these ligands. 
The reaction of [ReICl2(NO)(NCMe)3] with this neutral, triden-
tate ligand yields the neutral Re(I) complex [ReCl2(NO)(py-N
(Et)-py)]. This species contains mutually trans-chloride ligands, 
with the tridentate ligand coordinated in a meridional manner. 
The nitrosyl ligand displays the expected multiple bonding 
throughout, with an Re-N bond length of 1.742(2) Å and nitro-
gen-oxygen bond length of 1.202(3) Å; and a nearly linear Re-
N-O bond angle of 177.3(2)°. There is significant deviation 
from ideal octahedral geometry, mainly due to the small bite 
angle of the tridentate ligand. The Re-N bond length to the 
amine nitrogen trans- to the nitrosyl nitrogen is significantly 
longer than the bonds to the two aromatic amine nitrogens, as 
expected. {2.231(2) Å vs 2.085(2) and 2.091(2) Å}. Figure 5 
displays an ORTEP diagram of mer [ReCl2(NO)(py-N(Et)-py)]. 
Table 2 lists select bond lengths and angles from [ReCl2(NO)
(py-N(Et)-py)]. 
Continuing the evaluation of this structurally versatile family of 
ligands, we also examined reactions of the TcI-NO precursor 
                               Bond Lengths (Å)                           Bond Angles (°)                Bond Angles (°) 
Re - N1                  1.742(2)                          O1 - N1 - Re    177.3(2)       N3-Re-Cl1    86.99(7) 
Re - N2                  2.231(2)                          Cl1 – Re - Cl2          175.29(2)          N4-Re-Cl1    91.68(7) 
Re - N3                  2.091(2)                          N2 – Re - Cl2    90.38(6)       N1-Re-Cl1    92.64(8) 
Re - N4                  2.085(2)                          N3 – Re - Cl2    89.73(7)       N3-Re-N2    78.97(8) 
Re - Cl1                 2.4262(7)               N4 – Re - Cl2    90.06(7)       N4-Re-N2    78.54(9) 
Re - Cl2                 2.4352(7)               N1 – Re - Cl2    91.41(8)       N1-Re-N2  176.88(10) 
O1 - N1                 1.202(3)                          N2 – Re - Cl1    85.68(6)       N4-Re-N3  157.50(10) 
                                                                      N1 – Re - N3            103.59(10)       N1-Re-N4   98.90(10) 
Table 2 : Selected Bond Lengths (Å) and Angles (°) for the neutral ReI-NO complex [ReICl2(NO)(py-N(Et)-py)] . 
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[TcICl2(NO)(HOMe){PPh3)2] with the neutral tetradentate 
amine ligand (py-NH-NH-py). Here two major yellow products 
were identified and chromatographically separated. One cation-
ic complex was [TcICl(NO)(py-NH-NH-py)]Cl and it displays 
the chloride and nitrosyl ligands in a cis-orientation with the Tc
-N-O bond angle of 172.3°. The second yellow product yielded 
green crystals upon standing in solution for an for crystaliza-
tion.  The X-ray structural determination showed them to also 
be a cationic TcI-NO complex, [TcICl(NO)(PPh3)(py-NH-
NH~py)]+, which contains only three of the four nitrogen do-
Figure 6 – ORTEP diagrams of the TcI-NO complex [TcICl(NO)(py-
NH-NH-py)]+Cl- and the cationic TcI-NO complex [TcICl(NO)(PPh3)
(py-NH-NH~py)]+Cl-. 
nors of the tetradentate ligand coordinated. We hypothesize that 
triphenylphosphine from the precursor eluted with the yellow 
product and eventually replaced the second chloride ligand dur-
ing the prelude to crystalization, causing the yellow to green 
color change. The three coordinate tetradentate ligand displays 
one pyridine arm pendant, and the phosphine, chloride and nitro-
syl ligands arranged in a facial manner. The Tc-N-O bond angle 
here was 176.3°. The structures of these two TcI-NO cationic 
complexes are displayed in Figure 6. 
The ReI-NO complex [ReIBr2(NO)(NCMe)3] reacts with the 
Figure 7 – ORTEP diagrams of the ReI-NO complex [ReBr2(NO){py-
CH2NH~(CH2CH2N(CH2-py}2], and the dicationic ReI-NO complex 
[Re(NO)(N5)](BPh4)2. The tetraphenylborate anions have been omitted 
from the dicationic complex for clarity.  
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potentially pentadentate-N5 ligand N1,N1,N2-tris(2-
pyridinylmethyl)-1,2-ethanediamine in dichloromethane at room 
temperature to yield a mixture of a brown immobile species and 
a bright orange mobile species which were separated chromato-
graphically.  The orange species was determined to be [ReBr2
(NO){py-CH2NH~(CH2CH2N(CH2-py}2], which contains the 
pentadentate ligand coordinated in a bidentate manner, with the 
three remaining amine moieties dangling in a pendant manner. 
This suggests that under the ambiant reaction conditions em-
ployed and in a non-polar solvent, the ReI-NO precursor is more 
strongly bound to the halide ligands and the acetonitrile cis- to 
the nitrosyl core than was anticipated, a phenomenon previously 
reported for this rhenium complex. The analogous reaction in 
methanol yields the dicationic, fully chelated ReI-NO species 
[Re(NO)(N5)](BPh4)2. This dark brown species is precipitated 
from the methanol reaction mixture with addition of excess so-
dium tetraphenylborate. Figure 7 below displays the ORTEP 
diagrams for these two ReI-NO complexes. 
Complex M-N (Å) N-O (Å) M-N-O (°) At*        
[TcCl2(NO)(NCCH3)(PPh3)2]  1.781 (5)  1.192(5)  176.8(7)            Cl  
[TcCl2(NO)(PNPpr)] (mer) 1.751(5)  1.163(6)  177.9(4)            Cl 
[TcCl2(NO)(PNPpr)] (fac) 1.758(4)  1.184(6) 173.0(4)            N(R3)** 
[TcCl(NO)(SC5H4N)(PPh3)2]  1.748(4)  1.196(5)  177.7(3)            N(py)** 
[Tc(NO)(SC5H4N)2(PPh3)]  1.7497(12)  1.1941(17)  173.35(12)  N(py)** 
[Re(NO)(N5)](BPh4)2]  1.758(1)  1.190(2)  173.8(1)            Br  
[ReBr2(NO)(NCMe)(N5)]  1.737(8)  1.21(1)  174.4(7)            Br  
[TcCl2(NO)(N3)]  1.744(4)  1.187(6)  172.5(4)            N(R3)** 
[TcCl(NO)(N3)(PPh3)]Cl  1.796(3)  1.088(3)  178.4(2)            Cl 
[TcCl(NO)(N4)]Cl 1.751(3)  1.189(3)  172.3(3)            N(R2)** 
[TcCl(NO)(N4)(PPh3)]Cl 1.723(7)  1.216(9)  176.3(5)            N(py)** 
[ReBr2(NO)(CH3CN)3]  1.737(8)  1.21(1)  174.4(7)            Br 
[ReCl2(NO)(N3)] 1.736(5) 1.187(6) 177.6(5)           N(R3)** 
[ReCl2(NO)(N3)] 1.752(6) 1.212(7) 176.2(5)           N(R3)** 
Table 3  
*      - At = atom located trans- to the nitrosyl ligand 
**    - N(R2) = secondary amine, N(R3) = tertiary amine, N(py) = aromatic amine 
5. CONCLUSION 
The established TcII- and ReII-nitrosyl precursors [M(NO)X4]- 
and [M(NO)X5]2- form unstable reaction products which are 
very difficult to isolate cleanly. This isn’t the case with the MI-
nitrosyl precursors. The results presented here establish that 
various the various bi-, tri-, tetra- and pentadentate ligands we 
have examined react effectively with the TcI-nitrosyl and ReI-
nitrosyl precursors. And depending on the chelate, form stable 
complexes incorporating various groups coordinated at the site 
trans- to the nitrosyl group. The presence of different donor 
groups at the site trans- to the nitrosyl group induce slight vari-
ations in the bending in the Tc-N-O bond. In fact the differences 
in M-N-O bond angle between a complex with a halide and an 
amine is at best marginal, and may reflect crystal packing forces 
rather than any inductive effect from the trans- ligand. See Ta-
ble 3 above. 
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